Title : Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study.

Pub. Date : 2014

PMID : 24940053






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: The PATHOS study demonstrated a significant reduction in COPD hospitalizations and pneumonia-related hospitalizations in patients treated with budesonide/formoterol versus fluticasone/salmeterol (-29.1% and -42%, respectively). Budesonide COPD Homo sapiens
2 In the base case, the treatment of a patient for 1 year with budesonide/formoterol led to a saving of $499.90 ($195.10 for drugs, $193.10 for COPD hospitalizations, and $111.70 for pneumonia hospitalizations) corresponding to a -27.6% difference compared with fluticasone/salmeterol treatment. Budesonide COPD Homo sapiens
3 CONCLUSION: Treatment of COPD with budesonide/formoterol compared with fluticasone/salmeterol could lead to a reduction in direct health care costs, with relevant improvement in clinical outcomes. Budesonide COPD Homo sapiens